BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 66.64
-1.92 (-2.80%)
At close: May 8, 2026
SHA:688166 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,265 | 1,190 | 1,248 | 1,161 | 1,013 | 1,050 |
Other Revenue | 34.14 | 34.14 | 34.27 | 18.34 | 4.04 | 2.25 |
| 1,300 | 1,224 | 1,283 | 1,180 | 1,017 | 1,052 | |
Revenue Growth (YoY) | 9.09% | -4.59% | 8.73% | 15.94% | -3.33% | 34.00% |
Cost of Revenue | 616.32 | 615.41 | 560.51 | 542.9 | 390.95 | 470.07 |
Gross Profit | 683.29 | 608.23 | 722.04 | 636.61 | 626.38 | 582.34 |
Selling, General & Admin | 224.64 | 232.53 | 210.87 | 180.46 | 184.98 | 145.56 |
Research & Development | 363.46 | 304.95 | 297.45 | 248.59 | 207.02 | 173.29 |
Other Operating Expenses | 1.2 | -0.49 | 1.39 | -1.59 | 5.22 | 4.22 |
Operating Expenses | 614.44 | 556.67 | 521.27 | 428.37 | 395 | 333.18 |
Operating Income | 68.85 | 51.56 | 200.76 | 208.24 | 231.38 | 249.16 |
Interest Expense | -66.57 | -62.96 | -52.44 | -44.42 | -23.71 | -9.7 |
Interest & Investment Income | 4.72 | 5.55 | 10.96 | 17.99 | 6.2 | 10.14 |
Currency Exchange Gain (Loss) | 6.09 | 6.09 | 1.92 | 2.6 | 12.99 | 4.63 |
Other Non Operating Income (Expenses) | -7.74 | -2.07 | -2.14 | -1.88 | -2.17 | -1.77 |
EBT Excluding Unusual Items | 5.35 | -1.83 | 159.07 | 182.54 | 224.68 | 252.46 |
Impairment of Goodwill | -3.12 | -3.12 | -4.38 | - | - | - |
Gain (Loss) on Sale of Investments | -4.35 | -5.54 | -17.33 | -15.26 | -3.39 | 0.79 |
Gain (Loss) on Sale of Assets | -0.5 | -0.5 | -0.15 | -0.25 | -0.01 | -0.26 |
Asset Writedown | 0.02 | - | - | - | - | - |
Other Unusual Items | 24.89 | 24.89 | 19.99 | 21.74 | 20.93 | 4.47 |
Pretax Income | 22.3 | 13.91 | 157.2 | 188.77 | 242.21 | 257.46 |
Income Tax Expense | -28.82 | -23.05 | 15.94 | 15.35 | 30.78 | 19.9 |
Earnings From Continuing Operations | 51.11 | 36.95 | 141.26 | 173.42 | 211.43 | 237.56 |
Minority Interest in Earnings | -0.26 | 17.56 | 47.9 | 29.04 | 28.2 | 6.39 |
Net Income | 50.85 | 54.51 | 189.17 | 202.47 | 239.62 | 243.95 |
Net Income to Common | 50.85 | 54.51 | 189.17 | 202.47 | 239.62 | 243.95 |
Net Income Growth | -63.17% | -71.18% | -6.57% | -15.51% | -1.77% | 43.60% |
Shares Outstanding (Basic) | 428 | 419 | 420 | 422 | 413 | 407 |
Shares Outstanding (Diluted) | 428 | 419 | 420 | 422 | 413 | 407 |
Shares Change (YoY) | 1.41% | -0.24% | -0.34% | 2.10% | 1.61% | -1.87% |
EPS (Basic) | 0.12 | 0.13 | 0.45 | 0.48 | 0.58 | 0.60 |
EPS (Diluted) | 0.12 | 0.13 | 0.45 | 0.48 | 0.58 | 0.60 |
EPS Growth | -63.68% | -71.11% | -6.25% | -17.24% | -3.33% | 46.34% |
Free Cash Flow | -172.29 | -128.22 | -11.64 | -209 | -415.47 | -733.59 |
Free Cash Flow Per Share | -0.40 | -0.31 | -0.03 | -0.49 | -1.01 | -1.80 |
Dividend Per Share | 0.016 | 0.016 | 0.096 | 0.096 | 0.114 | 0.120 |
Dividend Growth | -83.33% | -83.33% | - | -15.79% | -5.00% | 42.86% |
Gross Margin | 52.58% | 49.71% | 56.30% | 53.97% | 61.57% | 55.33% |
Operating Margin | 5.30% | 4.21% | 15.65% | 17.66% | 22.74% | 23.67% |
Profit Margin | 3.91% | 4.46% | 14.75% | 17.16% | 23.55% | 23.18% |
Free Cash Flow Margin | -13.26% | -10.48% | -0.91% | -17.72% | -40.84% | -69.71% |
EBITDA | 223.99 | 195.13 | 298.05 | 275.07 | 271.03 | 283.34 |
EBITDA Margin | 17.23% | 15.95% | 23.24% | 23.32% | 26.64% | 26.92% |
D&A For EBITDA | 155.14 | 143.57 | 97.28 | 66.83 | 39.65 | 34.18 |
EBIT | 68.85 | 51.56 | 200.76 | 208.24 | 231.38 | 249.16 |
EBIT Margin | 5.30% | 4.21% | 15.65% | 17.66% | 22.74% | 23.67% |
Effective Tax Rate | - | - | 10.14% | 8.13% | 12.71% | 7.73% |
Revenue as Reported | 1,300 | 1,224 | 1,283 | 1,180 | 1,017 | 1,052 |
Advertising Expenses | - | 1.69 | 2.28 | - | 0.52 | 1.01 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.